N
Google TrendARSENAL (5000+) — Arsenal v Lille: Champions League – live
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:arsenal5000+anthony gordon500+montez sweat2000+rob lowe1000+tanner hudson500+frozen frenzy200+huevo1000+payton pritchard1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Complement-targeted thera" (30 stories)

Top Headline Story

MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio
Lead StoryOphthalmology Timesgeneral
Feb 6

MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQdFFqSjh1SEZXdjBQbzJFVXZqdFFfRjhzdlRKX1lhYlFKWVFRX1drNE5qWkoxa3p2MXZMdkNKbjlWYWoxUVpIMmxFbVU5VUJlVzlpaUd1emNPZkZscXFkT0d4SHRkdm05SkMyRXNCdy12bkd2VFpoTk1DamUyTUtGdGRBNjNqRGJZZzNUZGw0bDZycHM4ODNDOE9HaU9WUlhWVURtRGh5SW9wR2d4bEtYbW8wek1KalE?oc=5" target="_blank">MeiraGTx Licenses complement-targeted geographic atrophy program from ZipBio</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+16m ago

arsenal

Arsenal v Lille: Champions League – live

Filter stories
500+16m ago

anthony gordon

Anthony Gordon's first Barcelona goal, Manuel Neuer's mistake and Djed Spence's Inter debut in the Euro Debrief

Filter stories
2000+26m ago

montez sweat

Bears DE Montez Sweat suspended 2 days for drug violation

Filter stories
1000+36m ago

rob lowe

Ben Shapiro’s Star-Studded ‘Confession’ Film Includes James Franco, Rob Lowe And More

Filter stories

Search Results for "Complement-targeted thera"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Complement-targeted therapies for transplant-associated thrombotic microangiopathy: recent advances
Frontiersgeneral

Complement-targeted therapies for transplant-associated thrombotic microangiopathy: recent advances

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxQQ1FJNHd4OHJuZUIxVWFZLWZoWDV1Umxjd19WZ005WUR0b3hzZmNySXJ0emY1QXZUNDRjcjB0NmpVaERlV25WWXZqY0E0aFpSb0tpblZQNW52blRDVFNmSXF0QkNobGlBcVlMRjBqR3RoRWgxSXVZUHExQlRWQkFTZV9JOVUxX3c4TDJTLWVlSFpSakFM?oc=5" target="_blank">Complement-targeted therapies for transplant-associated thrombotic microangiopathy: recent advances</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Targeted complement inhibition ameliorates the pathological and cognitive outcomes in repetitive mild closed head injury
Naturegeneral

Targeted complement inhibition ameliorates the pathological and cognitive outcomes in repetitive mild closed head injury

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5EUy01MFc3WTNJeG1RQW1hVEJJek5hYWRjbXVLUXpfZWVmcTdBdlBETERiUnJtenQwbUhkT1JhOEF0eFh0dTRDU0hsM0pDT3NzdDZvVmE1cllLalpLRDg4?oc=5" target="_blank">Targeted complement inhibition ameliorates the pathological and cognitive outcomes in repetitive mild closed head injury</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies
Cureusgeneral

Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQbkI5ZXFWMXBucllWSlZ0aVZkRG1tMVBZU3FEUGVSb0tsZ3N2VWhhY1ZUMU5aV2hBdXVmb3E1M0NSZkJoY2FDMEdOSXBrbEpFcTlRTHBtd2hUbS1ER2F2dkdmRUtfaWFvS1N2R2RoMm5Nb2J1SFZmNE5idzVvVldER09taHJhVmtOY08zX3NPMUNDRWRyZUdNMmdVaVA2YnA0WTlNMG5Ka0dDUjVRcEo1OEpHMWxVRGd6Wm1LZUtOeHE4RFNiZ0xpOXJpeW95dTg?oc=5" target="_blank">Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases
Frontiersgeneral

Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNelhObElOaFlJNkV2STZYQ1ZkSU1sVGlwNkx4dkxldlpGZzJzTTFRaE10c0Z3dkJGRkJfQ005QkpDT25DUGhINnZVQUt2TVRwS0I5WENyS3gwaGgwS0JBbEFKdHVZVmc5Z2ZGOE8wZHNSSllZT3FtOUdESjFZdXZBcDgxYUkzU3p3eXRldjA0c2VrZw?oc=5" target="_blank">Case report: Sequential complement inhibition and BAFF/APRIL blockade in progressive IgA nephropathy and IgA vasculitis nephritis: a report of two cases</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy
Ophthalmology Timesgeneral

First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxQM1F3Yk5WLXI2TWxDLTVxQ0wtSGt6cHRmYjI0VDdjaFdWZVlIN1NuRXAzck0zamNWajRhb0x4TERCcnRudEtfZ0hlc19feHgwV1JZaF9WTXBNQ1o2UFpFZlVQc3FnUGo2akg4V3Y5SG83VE8xdVZuaU15Q29qamxaUGJxUGFuYjg2TXVoNmdZdzFSNWtPOUNOUHFTVERZNW1la2FhRms1X3h5UzR6?oc=5" target="_blank">First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
New frontiers in myasthenia gravis therapy: FcRN inhibitors, complement inhibitors and anti-CD-19 therapy
Mayo Clinic Pressgeneral

New frontiers in myasthenia gravis therapy: FcRN inhibitors, complement inhibitors and anti-CD-19 therapy

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPeHl0RDU5dWRLLVlIVnVpSnlIenczZmNYWVhJYnJ2SzJRQXg3cTNnQnc0RW9fUjhPOWx5dUtyUEtlM1lmamQ3LTc1SWJWeDRvaGVnTnprQ1RLT01ZdzVBV045MGRFTjdhT3FyWmt4MHZ2R3RaVC1TbnVsMlhoX3hkV3psaFZTU1NHVXF6YjlyeThsbmhuOFNKeUNlQnNHZHJHZW1kV2ZZZXBPRDJ5aDF5MHBEa2VCWEhwT1NvWWoxXzdzZF94bHFQYkM1N1pUWWlXM3RnTUtYSVczMDNhUUMzdg?oc=5" target="_blank">New frontiers in myasthenia gravis therapy: FcRN inhibitors, complement inhibitors and anti-CD-19 therapy</a>  <font color="#6f6f6f">Mayo Clinic Press</font>

Read Full StoryMore like this
Europe withdraws Tavneos as AAV treatment and opens a gap for other complement inhibitors?
European Biotechnology Magazineworld

Europe withdraws Tavneos as AAV treatment and opens a gap for other complement inhibitors?

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQ0Q1Tzc4T0RDLUlVaWY5MDEtOUZEYzdBZzBwOFlNV2xoUGprUUVIWTZIOHgtQ0JUVVpuZWw1VHlXZ2I2U25LR1NyQXZHX3NsUy1PRDBuT3cwaU5CYmhrRFoweUlRWTIySEJwN0lmSEFZYmlrQVhzR05EcEZrb0ZrZVI1elAtWjBNVGowc0JUWlVLb0tjak04Nnd3eDNFdUdpM1hVM21DdGxsdmRYZXNSdmVsU2lWczVVZ3k1cGxMWC1DVjktZjk5S1pvTTQ1ekQyRlhJ?oc=5" target="_blank">Europe withdraws Tavneos as AAV treatment and opens a gap for other complement inhibitors?</a>  <font color="#6f6f6f">European Biotechnology Magazine</font>

Read Full StoryMore like this
Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera
BioSpacetech

Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera

<a href="https://news.google.com/rss/articles/CBMihgJBVV95cUxNejR3SFpmVjE2WFpkOXpiSU1ld3M2QU9pZ1QyV25VSHN6emJPVUVCMTNtaTQydUE5YXpxNWNrYVNSNEZueVRBd0RlRE81NXhna1JOUXd1azNEUzdZQzBic1dnbVNsQVhGc1VmMHp2ckRNWVNodFRjNmlXOEdvSS1TTHdndnFkMWFBUlhPczdJVlZBZmgxdHBrOEJ5ekxVVktnbEpqM0FLeUZYY3VIU2RLR0RWTkdPSWJFUnJjMEJEbkpYZnRodGdDMXR5Yk9kRVZsa3ZvazZqNzN6bkJweEgyS01nbWxROTFsZGZKWlNCZWZDMC1IWENSeko0UDg3V2NsQVBQU2ZR?oc=5" target="_blank">Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Creative Biolabs Supports Next-Generation Complement and Cell Therapy Research
nrtoday.comgeneral

Creative Biolabs Supports Next-Generation Complement and Cell Therapy Research

<a href="https://news.google.com/rss/articles/CBMikAJBVV95cUxQb1lrcVMzamg2d2RYVGNpdmFlMkF5b2JNMjJxMm9wRWQ1UUZ5Y0RWak9hMFBCNS1rZnp2WHNnTXpSaW5DN2NuY0N1VjZCUVIwR2I3azB3ZnY2bUNEb01kSlNxYmhpTDUxLVJvV1hMdXYtUEllTTRoWGZ1R0tmWDBYS0RXREZjQnhpSk1BdUljQ3JiX2JnYzdWdkZfM21HNHQ4cGV2VENkVTlrSWRmd0ZpMVB2bVJxeHBrUXhUV2FhMENIVllORU1oN3lxaEFybUZBdkY4OWlZLTloQlJJTlpIWlJyOUZEUDlQVGVtelNPZEYwR2dwYTZ0NDFpTllHVEptQ0lTZTFtMmhvWFVaVUtXWA?oc=5" target="_blank">Creative Biolabs Supports Next-Generation Complement and Cell Therapy Research</a>  <font color="#6f6f6f">nrtoday.com</font>

Read Full StoryMore like this
IgA Nephropathy in 2025: Year in Review
HCPLivegeneral

IgA Nephropathy in 2025: Year in Review

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBQMHJXRW9tZ1piVGcwcC03T3FMQlo5OGFEemMySU1nbUdlTVREMTNIOW1rb3ZNTGFKUGJEUDhrQV9NWE5tZk9DU0FSenBQby1IN1JNQ0h6dUdnMzN5U3NnMlp2OGJUMnRjb1ZFbmxB?oc=5" target="_blank">IgA Nephropathy in 2025: Year in Review</a>  <font color="#6f6f6f">HCPLive</font>

Read Full StoryMore like this
Innate immunity: current understandings and future perspectives
Natureworld

Innate immunity: current understandings and future perspectives

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE4zR19vNG9tWlo3aUc1TzNjaW5xNVhkbEgzekJMR2lOM1p4UkI4QmNoQThSZzR5a0liODdiYU0tcjhCUktKajBoTWNHcUZsdWt4dGd4VjNtcW03V0piTGpZ?oc=5" target="_blank">Innate immunity: current understandings and future perspectives</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Cemdisiran siRNA Therapy Demonstrates Efficacy in Myasthenia Gravis
MedPage Todaygeneral

Cemdisiran siRNA Therapy Demonstrates Efficacy in Myasthenia Gravis

<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE9YMEZHeU5MNEtRYXUzYnhKN211MTBSeDVPWUdJSFM3VThzNkpxVFJ1UVhsQVlnOHFNQy1zcEExeWRZdmtRMm5yTk9OSFN1RFQza2FnN1V3MnNkcjZOcVd2UjAwWV9KUQ?oc=5" target="_blank">Cemdisiran siRNA Therapy Demonstrates Efficacy in Myasthenia Gravis</a>  <font color="#6f6f6f">MedPage Today</font>

Read Full StoryMore like this
2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate
2 Minute Medicineworld

2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate

<a href="https://news.google.com/rss/articles/CBMivwJBVV95cUxNTnN4MEhDV3U1YURYdVZIeHNZT29jVV8waGdyRjJvX0E5YkR0eUwzLTVPVlJTcEVOaGRQbXlfWmdVSlRKc3pnNHpKQUlXNFVnU0dUMDhpMjd2U2RtQkZSV1RSbFR1UjE2ei1SZHpiZ0plS1FkSDZ3blRnR0tuaW95NlR1TlJ3Z3g5Q05RdTgtTTNCRGNJOWdVT3dxTXJOYmItMUhlTHZ6eWExME9QdWJ6Uk8zMnNOdDI4T3pRb2xnOVpLbF9rSGVTNW54QzIzc0ltZUNFSjlTNUx1ckd0WWhxUUlSNk52czZaWXZsSHZEd1hJM1NKWGI0ZG9LYUdCbmFZMUN3U0hBa3hCWjRacGhKdGZKWGlyYmpCckFOSk1XZHJkNlF2UTJXSVdlWEs0VHZZTVI0UjRWSk56WWFlcEtv?oc=5" target="_blank">2 Minute Medicine: Pharma Roundup – New oral gonorrhea antibiotic Nuzolvence (zoliflodacin), late‑December cardiovascular and oncology drug approvals, first targeted complement inhibitor therapy for HSCT‑TMA (Yartemlea), and antibody‑drug conjugate</a>  <font color="#6f6f6f">2 Minute Medicine</font>

Read Full StoryMore like this
Breaking tolerance in the glomerulus: complement as a driver and therapeutic target in IgA nephropathy
Frontiersgeneral

Breaking tolerance in the glomerulus: complement as a driver and therapeutic target in IgA nephropathy

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPbkg4bjc2Q0NPMzYxbGJhdEh5ZDNodEZGNDdEMXZvUlVvdE8wczZpXzMxUTNlRDduLWF6aXJlUkg0VWVTdUVCUlgzaU1FTmxYLXdwcm1YNGpfT2NtZ1B3VzlDSjFLWU5WRGNkaEljVUhVWlVBNUgwUXVybXMtUlZZc3lPMTltcTVKQTRCaGlR?oc=5" target="_blank">Breaking tolerance in the glomerulus: complement as a driver and therapeutic target in IgA nephropathy</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine
Cureusgeneral

Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine

<a href="https://news.google.com/rss/articles/CBMilAJBVV95cUxQN1N1NUg1Y1BWTkVncGxDZTdLcjBqaVhJeFFWYjlzQzh3dF95VENVeWNOOU10dUNITzBHX0JIVWZlQ2ZuNUhwVVh5MlpPdUgxU0tZMXAxakktT01qRURMc0NLSi1kTlJRUnI3SHNNeGVGYzYyRThNNkpoYTlEbVFXeDRCWFFIVE4zZGxYNUYyUXFoUWQ1UVNfYnJ2VkozSmZRdUdpZjRNamRPMkdScl9Oa05CLV9yYjkxTzdXYjMtQUxoNGpjTUlNT0I4VnB0VkJnai1yYTRQV2I0dmpJd3ZIUU4yTW1LOWltZmFxSng0cFhUVFFvblBxclktcWJkdUZIZHJmRWRGbDRWNzVwOHN0bTM5bkw?oc=5" target="_blank">Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine</a>  <font color="#6f6f6f">Cureus</font>

Read Full StoryMore like this
The complement system as a target in cancer immunotherapy - Merle - 2024 - European Journal of Immunology
Wiley Online Libraryworld

The complement system as a target in cancer immunotherapy - Merle - 2024 - European Journal of Immunology

<a href="https://news.google.com/rss/articles/CBMib0FVX3lxTFBOWFQzTmFlUjg1Y0JQblVYQ1FiWVdWd1hCZlJ6SDhUeGJqUmlRek1pWG5SdmkzMnNrTS1aZTFTOFBVQ3dzT0REV3FNTERHQzVudFVBUWdodThTVlZSR0I4WmgzUkZ6UVN4OTZ3RmUyRQ?oc=5" target="_blank">The complement system as a target in cancer immunotherapy - Merle - 2024 - European Journal of Immunology</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Beyond anti-VEGF: The next wave in retinal therapy | Eye Care Network - Modern Retina
Ophthalmology Timesgeneral

Beyond anti-VEGF: The next wave in retinal therapy | Eye Care Network - Modern Retina

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQYnpZOW9JZFc3WWx5eTRPWUNualNLQ295aHlDb2k3cGNESnQ2QkFBcV9KMmRkNGt6a29nYUxsM0dpRkM3RkhpRTRpWk9zLU00WEFqa19EQjdKc2JDTjdzZXRTYnNnVFBkcWk0WWdWTTUzTnRqbDJfOFhPTFJRWGNDUnhBU3VBbGFEckVjcTNTZUdOT0k?oc=5" target="_blank">Beyond anti-VEGF: The next wave in retinal therapy | Eye Care Network - Modern Retina</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade
Natureworld

A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1TVUFwVHNLXzZnZmQzY0RfSDBxTFotQ2tQQVhDcE93eDBZNF9mLUgyXzRDeUxGQ3k3WU9kNHdadzRoYUMzdzZrYm9Kc0VHSDF1QWg5Z1BYNkJ6Mld0M3g0?oc=5" target="_blank">A novel long-acting C5a-blocking cyclic peptide prevents sepsis-induced organ dysfunction via effective blockade of the inflammatory cascade</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies
Frontiersworld

Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQZmlUWWdYTDRvUEJ1ZXpKQk8wMGdWZF9vaC1RU1ZIQ2Q4ZXBhcXJESWpwWXJ5WEsyMzFidkRLLWdVSmpYSk42b3F5c1AyVW9HbUpUeWNQeVg2NkZvUGFtMTVab3ZUcEFuVjgzQkdxVmRoZ1RDMU1KZkowa1RaZ2dUOE15RUxCeks2cEtZLXFsdjA?oc=5" target="_blank">Complement activation in immunological neurological disorders: mechanisms and therapeutic strategies</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
The role of complement in tumor immune tolerance and drug resistance: a double-edged sword
Frontiersworld

The role of complement in tumor immune tolerance and drug resistance: a double-edged sword

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNRlBSUW5EQW9iMEZxVmo3TFl3alhUTW12X05vTllud09wM0owZXVxSWxCQVowTXNFcGdLOHFUekhVYnduOEQ1TDRDMDN6c09CbmNETWJIWm1zcWEzMVdiMF9iZWxreEp6V0ZHMUhqRFk2WDFPY3l3UThuc0V2NnBJNkJjMVFrWDVCTUMtN3A2OTJVUQ?oc=5" target="_blank">The role of complement in tumor immune tolerance and drug resistance: a double-edged sword</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Is complement therapy the path forward for geographic atrophy? | Eye Care Network - Modern Retina
Ophthalmology Timesgeneral

Is complement therapy the path forward for geographic atrophy? | Eye Care Network - Modern Retina

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNRTJiSENHc3NQbUFrNEJ4d1ZDYW0ydE84bVEwVHVZR21NTzEtd0NUdWxXLVRzTXBGZGE5VndUQ1g5SDg0VXNnS3h5Y000ZHlET1pnVnlLb2dJRFZaQmFzNG92V3RiWUZtM05LUzZxc0YxSmQ1MGJJcTJ0R2pKVzY1OWMyWVBQN1g0bDN0elJEdWRJUUZnMDUtdjV0ZXhIeHJjc3FGRw?oc=5" target="_blank">Is complement therapy the path forward for geographic atrophy? | Eye Care Network - Modern Retina</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection | Signal Transduction and Targeted Therapy
Naturegeneral

Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection | Signal Transduction and Targeted Therapy

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5SZEk4WHNmTVREMVFJLVdTeUtJbDFNWnJWdmgyeW1rekNzOVNOZVhtSFZYVWg5cV9HczZGSGtZNjE1QjNTTmNtejdhX1FJNG5nc1A5bm1ON21ld1NWXzhB?oc=5" target="_blank">Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection | Signal Transduction and Targeted Therapy</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Is complement therapy the path forward for geographic atrophy?
Ophthalmology Timesgeneral

Is complement therapy the path forward for geographic atrophy?

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOY0kyS3Bmd2p1R3prZ3VwNEd5QV91LWdwQ1ZFOUFHVkZKN2pIbTdBVUFGZVRBSHVKSThkTGUtQzA3eWZkZG5rLTVKalVxMXJGNGt2YkxqQkJsUnJoSGEzSWVPQjhGX2c3UVpzUFh1OG9BeFJJNUdnYkd0MmJKcTYxU2ZEUWstb2VqX2ZsMzZpaGZ2RUxSYWgxQXo4VlVwMWxiaUp6YzV0TlRsTE0?oc=5" target="_blank">Is complement therapy the path forward for geographic atrophy?</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage
Frontiersgeneral

Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxNM2RoZ0FDOE5SNDZabklVMFA3U2dTbU44ZzFIUFRRanRmMV9YbFp4TXF0OU1iNU9vWkxNc01rTE9tWUFGYlhQMTZBY3hpTnRPTDlkbmQyTlgwMU1WeGw2dUpkTmRxYm45cDJxdkxXd01hWHJMRXRkclV5dzltRldMUnBUU0dWS0pZeFBnX0p2Ti1OUQ?oc=5" target="_blank">Complement in acute kidney injury: a convergent pathogenic pathway in multifactorial renal damage</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Complement in human disease: approved and up-and-coming therapeutics
The Lancetgeneral

Complement in human disease: approved and up-and-coming therapeutics

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNRWZMOFRmcUlZVzhtcmVVZmlZSGxBX0t0YUtXY0ttck02anZ3dnhLX1JlN0tDOHFXV25IRG1HM3cxT19pM2NOZHYtcGhiakJHQVVMQ0RfYkFDTm95ZTRBeG0tU0duazRCZm9EMWI3WG9zTXpEZkVDNVh4S01nMjBYZ0w2SFB2dGc3X21v?oc=5" target="_blank">Complement in human disease: approved and up-and-coming therapeutics</a>  <font color="#6f6f6f">The Lancet</font>

Read Full StoryMore like this
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial
Natureworld

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE5fZzdVOFlDTHRYN0xfeFc3ckhhS2M1Vlk3SEhpaUdmS2dtbGVxNl9lei0tZy1GMV9HaWJZWURqVTRJYVQtUldpX3QwSlk1U3R3T25IcFVwNHkzbG0wbWxn?oc=5" target="_blank">Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery
Wiley Online Librarygeneral

Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTFAtNzdGRGJpMk1ENjRkR1djNldNQXZQT1J5b0pGa29ONkhmSF9EUVVUT3duME8tTkI0WGFla0V3NTJsaURMcE9KblpFTXRBZUdHcGRVd25SeklaVXh6bGRUQWZWbXp3S1EtdFE?oc=5" target="_blank">Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery</a>  <font color="#6f6f6f">Wiley Online Library</font>

Read Full StoryMore like this
Targeting the C3 signaling axis of the complement system: immune microenvironment regulation and emerging therapeutic strategies for glioblastoma
Frontiersworld

Targeting the C3 signaling axis of the complement system: immune microenvironment regulation and emerging therapeutic strategies for glioblastoma

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxQVHVxWGVXaC1qYUxtaURpa1Mtd3loeXYtWFZjUkNoejRIOWVjWGhlLWRON1dqQnhVbC1LRXd0Y1JXWEhsNXhxQ2xzQVdWNVBTV1hBNXdZQjdSbEZ2dWd2bHdDVGFjcm1PT3pVYi10RV9kSDZFYzZnekNBajJhYTlrQVAxd1ZNUWd2R2J5Y3FPeV95Zw?oc=5" target="_blank">Targeting the C3 signaling axis of the complement system: immune microenvironment regulation and emerging therapeutic strategies for glioblastoma</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Complement, a target for therapy in inflammatory and degenerative diseases
Naturegeneral

Complement, a target for therapy in inflammatory and degenerative diseases

<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1iOVVQamM0VHUwZXJCVzU0bjdVNDgwaDQxNWpHdDM5bVFYaWM5a2VOOXA0LUY1UkN2NU9ZYXUwTzBHWlgxRzdLSjlwb0xhLTRj?oc=5" target="_blank">Complement, a target for therapy in inflammatory and degenerative diseases</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this